TASK Brooklyn’s primary role is to conduct clinical research trials into effective treatment for Multi-Drug Resistant TB (MDR-TB) and Extremely Drug Resistant TB (XDR-TB)
TASK Brooklyn facilities include:
- a 25 bed in-patient capacity and is based within the grounds of Brooklyn Chest Hospital (a state managed facility) which enables access to specialized hospital services, namely:
- Occupational Therapy
- Social work
Spacious facilities and amenities for study participants further include:
- Comfortable patient waiting areas
- Recreational facilities for day patients
- 6 dedicated passenger vehicles to transport participants
- Experienced and well trained DOT (directly observed therapy) staff who go out to see study participants and work with them in their home environment to support them during their treatment
- Access controlled and restricted areas for infectious disease control
- CCTV gated controlled access
- Ventilated treatment areas
- Under the leadership of Principal Investigator (PI) Professor Andreas Diacon, TASK Applied Science conducted the first and largest Bedaquiline clinical trial at this site, that established the efficacy and safety of Bedaquiline in treating Multi Drug Resistant TB. Bedaquiline was the first “new” TB drug in 50 years which brought hope and improved treatment outcomes for thousands of MDR-TB patients in South Africa and across the world.
- Renown as one of the highest recruiting centers for TB clinical trials.
- Studies completed at TASK Applied Science Brooklyn Site have been reported in various scientific literature.
- Study team at this site work closely with prominent international TB alleviation sponsors and is the preferred site for undertaking MDR-TB and XDR-TB studies due to successes in recruiting and accruing study participants.
TASK Brooklyn is also an ACTG accredited research site.